Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.

[1]  D. Rimm,et al.  Tissue microarray‐based analysis shows phospho‐β‐catenin expression in malignant melanoma is associated with poor outcome , 2003, International journal of cancer.

[2]  Lydia Sánchez,et al.  Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. , 2003, Blood.

[3]  Donald R. Miller,et al.  Melanoma incidence and mortality among US whites, 1969-1999. , 2002, JAMA.

[4]  D. Pinkel,et al.  Cyclin D1 is a candidate oncogene in cutaneous melanoma. , 2002, Cancer research.

[5]  L. Chin,et al.  p16(Ink4a) in melanocyte senescence and differentiation. , 2002, Journal of the National Cancer Institute.

[6]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[7]  M. Barbacid,et al.  Invasive melanoma in Cdk4-targeted mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Mihm,et al.  The Melanocytic Proliferations A Comprehensive Textbook Of Pigmented Lesions , 2001 .

[9]  C. Cordon-Cardo,et al.  HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. , 2001, Cancer research.

[10]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[11]  Yasodha Natkunam,et al.  Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry , 2001, Modern Pathology.

[12]  L. Chin,et al.  Genetic dissection of melanoma pathways in the mouse. , 2001, Seminars in cancer biology.

[13]  M. Lisanti,et al.  Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. , 2001, American journal of physiology. Cell physiology.

[14]  L. Chin,et al.  Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas , 2001, Molecular and Cellular Biology.

[15]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[16]  L. Chin,et al.  Murine models of malignant melanoma. , 2000, Molecular medicine today.

[17]  J. Nesland,et al.  Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  K. Weinberg,et al.  Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Hemminki,et al.  Analysis of G1/S checkpoint regulators in metastatic melanoma , 2000, Genes, chromosomes & cancer.

[20]  L. Akslen,et al.  Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[22]  A. Cesinaro,et al.  Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. , 1999, The Journal of investigative dermatology.

[23]  M. Piris,et al.  Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. , 1999, Blood.

[24]  M. Lisanti,et al.  Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells , 1999, The Journal of Biological Chemistry.

[25]  V. Tron,et al.  Expression of cell cycle regulators in human cutaneous malignant melanoma. , 1999, Melanoma research.

[26]  J. Nesland,et al.  Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.

[27]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[28]  G. Walker,et al.  Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets , 1998, Genes, chromosomes & cancer.

[29]  D. English,et al.  p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. , 1998, The American Journal of dermatopathology.

[30]  M. Lisanti,et al.  Caveolins, a Family of Scaffolding Proteins for Organizing “Preassembled Signaling Complexes” at the Plasma Membrane* , 1998, The Journal of Biological Chemistry.

[31]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.

[32]  Charles C. Wykoff,et al.  Recombinant Expression of Caveolin-1 in Oncogenically Transformed Cells Abrogates Anchorage-independent Growth* , 1997, The Journal of Biological Chemistry.

[33]  E. Hovig,et al.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.

[34]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[35]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[36]  D. Baltimore,et al.  Reduction of caveolin and caveolae in oncogenically transformed cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[38]  L. Karnell,et al.  The national cancer data base. Report on melanoma , 1994, Cancer.

[39]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[40]  R. Lew,et al.  Epidemiology of cutaneous melanoma. An update. , 1991, Dermatologic clinics.

[41]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[42]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[43]  Daan Brandenbarg.  The National. , 1892 .